BRPI0507104A - n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch - Google Patents

n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch

Info

Publication number
BRPI0507104A
BRPI0507104A BRPI0507104-6A BRPI0507104A BRPI0507104A BR PI0507104 A BRPI0507104 A BR PI0507104A BR PI0507104 A BRPI0507104 A BR PI0507104A BR PI0507104 A BRPI0507104 A BR PI0507104A
Authority
BR
Brazil
Prior art keywords
mch
substituted
modulating effect
cyclohexylimidazolinones
production
Prior art date
Application number
BRPI0507104-6A
Other languages
English (en)
Inventor
Lothar Schwink
Thomas Boehme
Matthias Gossel
Siegfried Stengelin
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0507104A publication Critical patent/BRPI0507104A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Abstract

N-CICLOHEXILIMIDAZOLINONAS SUBSTITUìDAS COM EFEITO MODULADOR DE MCH. A invenção refere-se a heterocilos de N-cicloexila substituídos, bem como os sais fisiologicamente compatíveis e derivados fisiologicamente funcionais dos mesmos, a processos para produção dos mesmos, e ao uso dos mesmos como medicamento. São descritos compostos da fórmula I, Q(R2)~ n~, na qual os radicais têm os significados indicados, em como os sais fisiologicamente compatíveis dos mesmos para sua produção. Os compostos provocam, por exemplo, uma redução de peso em mamíferos e são apropriados, por exemplo, para prevenção e tratamento de obesidade e diabetes.
BRPI0507104-6A 2004-01-25 2005-01-25 n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch BRPI0507104A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004003811A DE102004003811A1 (de) 2004-01-25 2004-01-25 Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2005/000700 WO2005070898A1 (de) 2004-01-25 2005-01-25 Substituierte n-cyclohexylimidazolinone mit mch-modulatorischer wirkung

Publications (1)

Publication Number Publication Date
BRPI0507104A true BRPI0507104A (pt) 2007-06-19

Family

ID=34745115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507104-6A BRPI0507104A (pt) 2004-01-25 2005-01-25 n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch

Country Status (26)

Country Link
EP (1) EP1711473B1 (pt)
JP (1) JP2007518771A (pt)
KR (1) KR20060128955A (pt)
CN (1) CN1934090B (pt)
AR (1) AR047453A1 (pt)
AT (1) ATE383342T1 (pt)
AU (1) AU2005206308A1 (pt)
BR (1) BRPI0507104A (pt)
CA (1) CA2554233A1 (pt)
CY (1) CY1107429T1 (pt)
DE (2) DE102004003811A1 (pt)
DK (1) DK1711473T3 (pt)
ES (1) ES2297667T3 (pt)
HR (1) HRP20080077T3 (pt)
IL (1) IL176917A0 (pt)
MA (1) MA28345A1 (pt)
MY (1) MY139107A (pt)
NO (1) NO20063757L (pt)
PE (1) PE20051091A1 (pt)
PL (1) PL1711473T3 (pt)
PT (1) PT1711473E (pt)
RS (1) RS50543B (pt)
RU (1) RU2006130626A (pt)
TW (1) TW200604182A (pt)
UY (1) UY28726A1 (pt)
WO (1) WO2005070898A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
WO2008068265A1 (en) 2006-12-05 2008-06-12 Janssen Pharmaceutica N.V. Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
KR100893394B1 (ko) * 2007-05-11 2009-04-17 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
DE102008060967A1 (de) * 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
PL223830B1 (pl) 2012-04-03 2016-11-30 Univ Jagielloński Pochodne aromatycznych imidazolidynonów i ich zastosowanie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050044664A (ko) * 2001-12-04 2005-05-12 쉐링 코포레이션 비만 치료용 ｍｃｈ 길항제로서의ｎ-아릴-ｎ'-아릴사이클로알킬-우레아 유도체
DE10233817A1 (de) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2554233A1 (en) 2005-08-04
EP1711473B1 (de) 2008-01-09
ES2297667T3 (es) 2008-05-01
AR047453A1 (es) 2006-01-18
HRP20080077T3 (en) 2008-03-31
CN1934090A (zh) 2007-03-21
PL1711473T3 (pl) 2008-05-30
ATE383342T1 (de) 2008-01-15
NO20063757L (no) 2006-10-11
JP2007518771A (ja) 2007-07-12
KR20060128955A (ko) 2006-12-14
TW200604182A (en) 2006-02-01
IL176917A0 (en) 2006-12-10
CN1934090B (zh) 2010-04-07
EP1711473A1 (de) 2006-10-18
CY1107429T1 (el) 2012-12-19
DE102004003811A1 (de) 2005-08-11
MY139107A (en) 2009-08-28
PE20051091A1 (es) 2006-01-23
PT1711473E (pt) 2008-03-07
DE502005002497D1 (de) 2008-02-21
DK1711473T3 (da) 2008-05-26
RS50543B (sr) 2010-05-07
AU2005206308A1 (en) 2005-08-04
MA28345A1 (fr) 2006-12-01
RU2006130626A (ru) 2008-02-27
UY28726A1 (es) 2005-08-31
WO2005070898A1 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
BRPI0507104A (pt) n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch
BRPI0507100A (pt) heterociclos substituìdos por arila, e método para a produção destes como medicamentos
BRPI0514310A (pt) 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos
BRPI0507198A (pt) derivados de bisariluréia
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
BRPI0407387A (pt) Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
UY28122A1 (es) Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
BRPI0513085A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, e uso das mesmas como inibidoras de dipeptidil peptidase
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
HN2009000784A (es) Dihidropirazolonas sustituidas
BRPI0515485A (pt) compostos heteroarila como betamiméticos para o tratamento de doenças das vias respiratórias
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BR112012029395A2 (pt) lactamas piperdinil-substituídas como moduladores de gpr119
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.